Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Jiangsu Hansoh Pharmaceutical Co., Ltd. (to 2018)
3
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for FGFR4 inhibitor, preparation method therefor, and applications thereof (US 11,667,631) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due Apr 1 to 3, 2027 · next Apr 1
Recent changes
- 3 of the patents on this record were granted since Aug 24, 2026
- Nov 17 US 12,797,480 Antibody-Drug Conjugate and Medical Use Thereof
- Nov 3 US 12,780,937 ANTI-TROP-2 Antibody, Antigen-Binding Fragment Thereof or Mutant Thereof, and Medical Use Thereof
- Oct 6 US 12,753,166 Salt Containing Piperazine Polycyclic Derivative, Crystal Form Thereof, Preparation Method Therefor, and Use Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,097,586 | Modified exedins and uses thereof In force · USPTO record | In force | USPTO record | |
| US 8,183,242 | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof In force · USPTO record | In force | USPTO record | |
| US 8,642,545 | Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,908,908 | Tenofovir prodrug and pharmaceutical uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,512,121 | [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof In force · USPTO record | In force | USPTO record | |
| US 9,840,525 | Crystal form of tenofovir prodrug, preparation method thereof, and method of use thereof In force · USPTO record | In force | USPTO record | |
| US 10,208,065 | Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,259,820 | Egfr Inhibitor, Preparation Method and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,428,081 | Egfr Inhibitor, Preparation Method and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,759,782 | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 32: 4 patents in force now held by others · 13 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
22 pending · 2 abandoned · 16 no status recorded